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 ABSTRACT 
 
 
 
THE OUTCOMES OF CARBAPENEM RESISTANT 
ENTEROBACTERIACEAE (CRE) INFECTED PATIENTS AND THEIR 
ASSOCIATION WITH ANTIBIOTIC THERAPY 
 
 
 
Introduction 
 
Carbapenem Resistant Enterobacteriaceae (CRE) especially Carbapenem producing 
CRE (CP-CRE) has emerged as a global threat which commonly associated with 
hospital acquired infection including blood stream infection, pneumonia, surgical site 
infection and urinary tract infection. Overall, isolation of CRE from any site 
whether this represents clinical infection or not was associated with poor outcomes. 
Despite their increasing burden, the most optimal treatment for CRE infections was 
largely unknown. Therefore, the aim of this study is to determine the outcomes of 
CRE infected patients and their association with antibiotic therapy. 
 
 
Methods 
 
This was a retrospective study conducted in Hospital Universiti Sains Malaysia 
from January 2013 till March 2017. The list  of CRE cases se lected  from 
Medical Microbiology & Parasitology laboratory. Patient‟s records were reviewed for 
demographics and clinical characteristics and those that meet the inclusion and 
exclusion criteria were included in this study. Archived isolates were further tested for 
MIC testing for meropenem, imipenem, ertapenem, doripenem and polymyxin B by 
using E test method. The results were interpreted according to CLSI guidelines. Data 
 
were analysed using SPSS Statistic version 22. 
 
 
 
 
 
x 
 
Results 
 
 
A total of 57 CRE infected patients and started on targeted antimicrobial therapy was 
 
included in the study. The most common infection related to CRE infection was 
 
pneumonia (29/57, 50.9%) followed by blood stream infection (15/57, 26.3%) and 
 
urinary tract infection (7/57, 12.3%) with Klebsiella pneuomoniae as a major CRE 
 
pathogen (54/57, 94.7%). Most of the patients were located in a medical ward and ICU, 
 
accounting for 42.1% (24/57) and 33.3% (19/57) respectively of the subjects. Majority 
 
of patients had underlying disease and the most common disease was chronic kidney 
 
disease (38.6%, 22/57) followed by diabetes mellitus (36.8%, 21/57). The all-30-day 
 
mortality in this study was 43.9% (42/57). Based on in vitro susceptibility testing on 
 
carbapenems, imipenem has the highest sensitivity rate (9/57, 15.8%) followed by 
 
meropenem (7/57, 12.3%) according to CLSI breakpoint 2012. All isolates were 
 
susceptible to polymyxin B. Most of the subjects in this study received monotherapy 
 
(33/57, 57.9%) compared to combined therapy (24/57, 42.1%). We found that no 
 
significant association between patient‟s outcome with monotherapy or combined 
 
therapy (p = 0.113) and also with the type of antimicrobial received. However, the 30- 
 
day mortality in combined therapy group much higher (13/23, 56.5%) if compare to 
 
monotherapy group (12/34, 35.3%). Out of 45 repeated samples cases, 82.2% (37/45) 
 
had achieved microbiological clearance. We found that no significant association 
 
between meropenem MIC levels with microbiological clearance (p = 0.641). 
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 Conclusion 
 
 
Overall, based on in vitro susceptibility testing polymyxin B is considered to be the 
 
most active in vitro agents against CRE. However, imipenem and meropenem still have 
 
a role in treating CRE infection especially as a combination therapy. Even though no 
 
significant association was found between antibiotic therapy with the outcome but the 
 
30-day mortality in combined therapy group much higher than monotherapy group. This 
 
could be bias as combined therapy was started among severe infection and critically ill 
 
patients. A larger sample size and prospective study (randomised control trial) may be 
 
needed to prevent bias in term of patient‟s selection on starting type of treatment 
 
regime. 
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 ABSTRAK 
 
 
 
KESAN JANGKITAN CARBAPENEM RESISTANT 
ENTEROBACTERIACEAE (CRE) KE ATAS PESAKIT DAN KAITAN 
DENGAN RAWATAN ANTIBIOTIK. 
 
 
Pengenalan 
 
CRE terutamanya CP-CRE, telah muncul sebagai ancaman global yang biasanya 
 
dikaitkan dengan jangkitan semasa pesakit berada di pusat rawatan termasuklah 
 
jangkitan saluran darah, pneumonia, jangkitan pada luka pembedahan dan jangkitan 
 
saluran kencing. Secara umumnya, isolasi CRE sama ada di sebabkan jangkitan atau 
 
tidak boleh membawa kesan yang buruk kepada pesakit. Di samping peningkatan kes 
 
jangkitan, rawatan yang optima untuk CRE secara umumnya tidak diketahui. Oleh yang 
demikian, kajian ini dibuat bertujuan mengkaji kesan jangkitan CRE terhadap pesakit 
dan hubungannya dengan terapi antibiotik. 
 
 
 
Tatacara kajian 
 
Kajian retrospektif ini dijalankan di Hospital Universiti Malaysia dari Januari 
2013 sehingga March 2017. CRE positif telah di kenal pasti daripada Makmal 
Mikrobiologi Perubatan & Parasitologi. Rekod pesakit di semak, maklumat di catat dan 
semua kes yang memenuhi syarat di masukkan ke dalam kajian. CRE yang di kenalpasti 
kemudian diuji untuk ujian tahap MIC dengan menggunakan teknik E test terhadap 
antibiotik meropenem, imipenem, ertapenem, doripenem dan polymyxin B. Keputusan 
 
MIC di terjemah mengikut panduan CLSI. Data dianalisa menggunakan perisian SPSS 
 
Statistic versi 22. 
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Keputusan 
 
Keseluruhan terdapat 57 pesakit jangkitan CRE yang menerima rawatan antibiotik. 
 
Jenis jangkitan CRE yang paling tinggi adalah pneumonia (29/57, 50.9%) diikuti 
 
jangkitan saluran darah (15/57, 26.3%) dan jangkitan saluran kencing (7/57, 12.3%) 
 
dengan Klebsiella pneumoniae sebagai penyebab utama (54/57, 94.7%). Kebanyakan 
 
pesakit adalah daripada wad perubatan dan unit rawatan rapi yang masing-masing 
 
adalah 42.1% (24/57) and 33.3% (19/57). Sejumlah besar pesakit mempunyai penyakit 
 
yang sedia ada dan kebanyakannya adalah penyakit buah pinggang kronik (38.6%, 
 
22/57) diikuti dengan kencing manis (36.8%, 21/57). Peratus kematian dalam masa 30 
 
hari selepas diagnosa jangkitan dibuat adalah 43.9% (42/57). Berdasarkan kepada ujian 
 
sensitiviti in vitro terhadap ubat-ubat carbapenem, imipenem mempunyai tahap 
 
peratusan sensitiviti yang paling tinggi (9/57, 15.8%) diikuti dengan meropenem (7/57, 
 
12.3%) berdasarkan panduan CLSI 2012. Semua isolasi di dapati sensitif kepada 
 
polymyxin B. Kebanyakan pesakit di dalam kajian ini menerima rawatan satu jenis 
 
antibiotik sahaja (33/57, 57.9%) berbanding rawatan kombinasi antibiotik (24/57, 
 
42.1%). Kami dapati tiada kaitan signifikan antara kesan jangkitan ke atas pesakit 
 
dengan rawatan satu jenis antibiotik atau rawatan kombinasi antibiotik (p = 0.113) dan 
 
juga jenis antibiotik yang diterima. Walaubagaimanapun, didapati kadar kematian 
 
dalam masa 30 hari selepas diagnosa jangkitan dibuat lebih tinggi bagi kumpulan 
 
pesakit yang menerima rawatan kombinasi (13/23, 56.5%) berbanding dengan 
 
kumpulan yang hanya menerima satu jenis antibiotik sahaja (12/34, 35.3%). Daripada 
 
45 kes yang mempunyai ulangan pengambilan sampel, 82.2% (37/45) telah mencapai 
 
kebebasan kuman. Walaubagaimanapun, kami dapati tiada kaitan yang signifikan antara 
 
tahap MIC meropenem dengan kebebasan kuman dari sampel ulangan (p = 0.641). 
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 Kesimpulan 
 
 
Secara keseluruhan, berdasarkan kepada ujian sensitiviti in vitro, polymyxin B 
 
merupakan antibiotik yang paling aktif terhadap CRE. Walaubagaimanapun, imipenem 
 
dan meropenem masih mempunyai peranan dalam merawat jangkitan CRE terutamanya 
 
sebagai salah satu rawatan kombinasi. Walaupun tiada kaitan signifikan antara rawatan 
 
antibiotik dan kesan jangkitan ke atas pesakit, didapati kumpulan rawatan kombinasi 
 
mempunyai kadar kematian dalam masa 30 hari diagnosa jangkitan lebih tinggi 
 
berbanding kumpulan yang menerima satu jenis antibiotik sahaja. Ini mungkin 
 
disebabkan oleh rawatan kombinasi kebiasaannya diberikan kepada pesakit yang 
 
mempunyai jangkitan yang teruk dan kritikal. Sampel saiz yang lebih besar dan kajian 
 
prospektif (randomised control trial) mungkin diperlukan bagi mengelakkan 
 
kecenderungan pemilihan pesakit terutamanya untuk menerima jenis rejim rawatan. 
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 CHAPTER 1 INTRODUCTION 
 
 
 
1.1 Introduction to Enterobacteriaceae 
 
 
 
1.1.1 Characteristics and taxonomy 
 
 
 
Enterobacteriaceae is among the most frequently encountered pathogenic bacteria in 
 
clinical samples (Framer, 1999). It is a Gram negative bacilli, non-spore forming, 
facultative anaerobes that ferment glucose and others sugars, reduce nitrate to nitrite, 
form catalase but do not produce oxidase except for Plesiomonas. Most are 
motile except for Klebsiella spp and Shigella spp and the motility is by having 
peritrichious flagella. For taxonomy of Enterobacteriacea, it is classified in the 
domain Bacteria, phylum Proteobacteria, class Gamma proteobacteria, order 
Enterobacteriales and family Enterobacteriacea. Taxonomy is a dynamic and on-
going process whereby new species and genera will continue to be added especially in 
the advent of 16s rRNA sequencing that can help in identifying many clinical and 
environmental isolates up to species level that unidentifiable by conventional method. 
To date there are 53 genera and over 170 named species of bacterial family of 
Enterobacteriacea with 29 of them are considered as medically important that known 
to cause infection in humans (England, 2015). Those medically important 
Enterobacteriacea members are Citrobacter, Edwardsiella, Enterobacter, 
Escherichia, Hafnia, Klebsiella, Morganella, Pantoea, Plesiomonas, Proteus, 
Providencia, Salmonella, Serratia, Shigella and Yersinia. 
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 1.1.2 Epidemiology 
 
 
 
Enterobacteriaceae can be found and widely distributed in the variety of environment 
 
sources including in soil and water. They mainly inhabit the lower gastrointestinal tract 
 
of humans and various animals, thus these organisms are often referred as enterics. 
 
However, these bacteria also have been found to colonized extraintestinal including 
 
oropharyngeal and vagina (Filius et al., 2005, Altoparlak et al., 2004). The severity 
of underlying disease, mechanical ventilation and the presence of nasogastric feeding 
tubes were associated with oropharyngeal Gram-negative bacteria colonization 
(Korona-Glowniak et al., 2012, Johanson et al., 1969). 
 
Most of medically important Enterobacteriaceae can cause a wide variety of infections 
in both healthy people and those with pre-existing illness either in the community or 
hospital setting. Colonized patients have a higher risk of hospital acquired o 
nosocomial infection than patients who are not colonized. Generally, those pathogenic 
Enterobacteriaceae can be classified into 3 groups: 
i) Coliforms that can rapidly ferment lactose eg E.coli and Klebsiella spp 
 
ii) Non-coliform which do not ferment lactose eg Proteus spp 
 
iii) True pathogen, eg Salmonella spp and Shigella spp. 
 
 
Both coliform and non-coliform are opportunistic pathogens with the infecting bacteria 
 
can be either exogenous or endogenous. Majority of nosocomial infections appear to 
 
arise from endogenous flora. However, coliform bacteria other than E.coli are 
 
frequently found in tap water or even in distilled or deionized water. They may persist 
 
or actively multiply in water associated with respiratory therapy or hemodialysis 
 
equipment that can lead to hospital outbreak (Marilyn,1996). Members   of 
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 Enterobacteriaceae are the most common Gram negative isolates in microbiology 
 
laboratories and can be isolated from numerous clinical specimen including blood, 
 
sterile body fluid and others non sterile sample including pus, urine or samples from 
 
respiratory tract. 
 
 
 
1.1.3 Pathogenicity factors 
 
 
 
Generally, the virulence factors of the pathogenic micro-organism depending on the 
 
ability of these organisms to enter, establish and multiplication in the host, avoidance of 
 
host defence mechanisms, causing tissue damage and exit. These properties are usually 
 
depending on the structural of the organism itself, the ability of the organism to produce 
 
toxins and the presence of genes that encoded a special virulence factors especially 
 
antimicrobial resistance genes (Finlay, 1997). 
 
 
Structurally, members of Enterobacteriaceae are rod in shaped measuring about 1 to 3 
 
μm in length and 0.5 μm in diameter with the presence of surface appendages including 
 
pili and flagella. They have both inner and outer phospholipid membranes, which 
 
enclose a periplasmic space that contains the peptidoglycan cell wall. The outer 
 
membrane is comprise of asymmetrical lipid bilayer with the inner part composed of 
 
mainly phospholipids and the outer part composed of lipopolysaccharide (LPS). 
 
 
 
Pili and the outer membrane protein have the adhesive properties which aid these 
 
bacteria to enter the host. Type 1 pili or also known as type 1 fimbriae are ubiquitous in 
 
Enterobacteriaceae. It is composed of a rigid rod formed by repeating subunits of the 
 
FimA protein with the tips of these pili contain a short fiber composed of FimH and 
 
FimG. The FimH which is type 1 fibrial adhesin will bind to mannose residues in 
 
3 
 glycoproteins and glycolipids on host cell surfaces that result in adherence and later 
 
bacterial invasion (Hung, et al 2002; Ofek, et al 1977). 
 
 
While the LPS which consist of lipid A, a core phosphorylated oligosaccharide with the 
 
repeating oligosaccharide side chains is a very potent virulence factors for the members 
 
of Enterobacteriaceae. Lipid A or also known as endotoxin is biologically active 
 
portion of LPS has the extraordinary potency to induce the innate immune response via 
 
signalling Toll like receptors 4 (TLR4) that lead to release of pro-inflammatory 
 
cytokines including tumor necrosis factor, chemokines, interlukin-6 and major 
 
histocompability complex receptors. The host response to LPS is the important factor in 
 
determining outcome gram negative bacterial infections (Miller, et. al). Other than 
endotoxin, many of the Enterobacteriaceae members able to produce toxins that 
capable to induce lysis of the host cells that cause tissue damage known as 
hemolysins (Marilyn, 1996) Besides that, these organisms also have the capability 
to produce additional surface polysaccharide, including enterobacterial common 
antigen, colonic acid and an envelope of surface polysaccharide known as capsule 
(Whitfield, 1999). In certain genera the capsules can be quite luxuriant causing 
highly mucoid colonial morphology such as Klebsiella and Enterobacter. These 
capsule provide the ability of these bacteria to avoid phagocytosis and killing by 
human serum. The K1 capsule produced by many E.coli strains has been implicated 
with bacterial survival while passing the blood brain barrier which leads to 
meningitis (Scholl et al., 2005). Other than that the capsule of Klebsiella pneumoniae 
are important for colonization of the urinary tract (Struve and Krogfelt, 2003) and the 
K54 capsule in E.coli is important for systemic infections (Russo and Singh, 1993). 
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 The other important pathogenicity factor in Enterobacteriaceae is by having a several 
 
highly efficient systems that scavenge iron from the host in order to proliferate and 
 
survived within the host. The proliferative capability of many invasive pathogens is 
 
limited by the bioavailability of iron as an essential element for their growth (Parrow et 
 
al., 2013). These systems are control by a ubiquitous regulator protein that activates 
 
gene transcription at low iron concentration. Most of these organisms have produced 
 
low molecular weight iron-chelating molecules known as siderophores and certains 
 
strains have the capability to bind and transport the heme (Mandell, 2015). 
 
 
 
As known, the Enterobacteriaceae family have genomic structure consists of a single 
 
circular chromosome which may include multiple plasmids of various sizes in the 
 
cytoplasm. These plasmids which are an extrachromosomal autonomously replicating 
 
DNA element play major roles in pathogenesis of the infection. Even though they are 
 
not considered as virulence factors per se, the encoded genes in the plasmids may 
 
contribute to the presence of virulence factors in certain bacteria. In addition, most of 
 
these plasmids are very promiscuous with regard of their ability to transfer the encoded 
 
genes between the others genera. The most concern now is the emergence and 
 
dissemination of broad host range plasmids containing antimicrobial resistance genes 
 
among the Enterobacteriaceae members that lead to global spread of multidrug resistant 
 
organism (Schultsz and Geerlings, 2012). 
 
 
 
1.1.4 Infection related to Enterobacteriaceae 
 
 
Enterobacteriaceae can cause a wide variety of infections includes community acquired 
 
infection and hospital acquired infection which can be occur as sporadic infection or 
 
outbreaks. As most of the Enterobacteriaceae members inhabit the human‟s 
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 gastrointestinal tract, the intraabdominal infection is primarily occurred due to the 
 
invasion of these bacteria through the mucous tissues or via the breaks of intestinal wall 
 
such in perforated appendix. Some of Enterobacteriaceae members can be transmitted 
 
by consumed contaminated food or water for example Salmonella, Shigella and E.coli 
 
(Enterotoxigenic E.coli or Enterohaemorrhagic E.coli). The extraintestinal  
infections can be occurred as the Enterobacteriaceae have the extended niche 
especially in those with these bacteria colonization. It is also known that these 
bacteria can be transmitted by person to person which an important transmission 
route in health care associated infections (HAI) which also can leads to outbreaks. 
The coliforms and Proteus spp. are the most commons Enterobacteriaceae members 
that cause community acquired infection. Those bacteria related to community acquired 
 
infection are usually having a known virulence factors. E.coli is among the species 
 
frequently isolated from clinical specimens known to cause infections including 
 
cholecystitis, cholangitis, urinary tract infection and bacteraemia. E.coli was found as a 
 
leading cause of community acquired urinary tract infection (Dias Neto et al., 2003). 
 
The pathogenic strains of E.coli differ from commensal organisms by which they 
 
produce virulence factors specific for each pathotype. Those related to urinary tract 
 
infection having a specific virulence factors include P-fimbriae and α-hemolysins 
(Bien et al., 2012). The E.coli 0157:H7 or also known as enterohaemorrhagic E.coli 
produce Shiga toxins can cause varying severity of the disease including watery 
diarrhoea, bloody diarrhoea, haemorrhagic colitis, haemolytic uraemic syndrome (HUS) 
and death (Nguyen and Sperandio, 2012). According to one prospective surveillance 
study from eight Asian countries, K. pneumoniae was the second most common 
pathogen (15.4%) causing community acquired pneumonia (Song et al., 2008) and it 
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 was associated with significant high mortality rate (29.7%) (Lin et al., 2015). P. 
 
Mirabilis usually related to complicated UTIs, such as patients with functional or 
 
anatomical abnormalities of urinary tract, especially those with urolithiasis as it has the 
 
capability to produce urease that promote further urolithiasis (Chen et al., 2012). 
 
 
Healthcare-associated infections (HAIs) were a major problem in hospitals 
 
Worldwide. Based on CDC 2016, HAI was defined as the infection fitted with the 
NHSN site-specific infection criterion and the date of event occurred on or after the 3rd 
calendar day of admission to an inpatient location where day of admission is 
consider as day one. The Enterobacteriaceae was found to be the most common isolates 
(28%) involved in HAIs and overall, 45% of these bacterial isolates were multidrug 
resistant (Morgan et al., 2010). According to CDC 2016, the HAI was further divided 
as central line-associated blood stream infection (CLABSI), catheter- associated 
urinary tract infection (CAUTI), surgical site infection (SSI) and ventilator-
associated pneumonia (VAP). 
 
 
 
1.1.5 Treatment 
 
 
 
Generally, the antimicrobial therapies that can be used to treat Enterobacteriaceae 
 
infections are fluoroquinolones, beta-lactams and aminoglycosides. The beta-lactam 
 
antibiotics which inhibit cell wall synthesis are widely used to treat infection that caused 
 
by Enterobactericeae members. The beta-lactams agents with antibacterial activity 
 
against enteric bacteria include amoxicillin, ampicillin, piperacillin, ticarcillin. 
 
However, in the presence of strain that can produce beta-lactamase enzymes limit of 
 
these beta-lactams agent usage as it can lead to treatment failure. Thus, they are 
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 commonly used in combination with beta-lactamase inhibitors such as clavulanic acid, 
 
sulbactam or tazobactam. 
 
 
 
According to the Ambler classification there are four molecular classes of β - 
 
lactamases namely, A, B, C and D. The genes that encode beta-lactammases enzyme 
 
AmpC type which an Ambler class C is present in Serratia, Citrobacter and 
 
Enterobacter (MacDougall, 2011). It can rapidly hydrolyze penicillins, cephalosporins, 
 
and monobactams but not inhibited by the beta-lactamase inhibitors. Treatment of 
 
Enterobacter infections with third-generation cephalosporins may select for mutant 
 
strains associated with hyperproduction of AmpC beta-lactamase that cause about 5% 
 
to 20% of these bacteria developed resistant during therapy (MacDougall, 2011). 
 
Approximately 33% of bloodstream isolates have been shown to contain E. cloacae that 
 
produce ESBL as well as AmpC beta-lactamases that make these strain not only 
 
resistant to third-generation but also to fourth-generation cephalosporins (Szabo D, 
 
2005). Thus, the use of these agents in Enterobacter spp infection should be avoided for 
 
the treatment of serious infections. 
 
 
 
The other important beta-lactamase enzyme was extended spectrum beta-lactamases 
 
(ESBLs) which an Ambler class A and D. The spread of ESBLs in health care setting 
 
which also has been found in community-acquired infections causing difficulty in 
 
treating Enterobacteriaceae infections (Valverde and Cantón, 2004). These β - 
 
lactamases enzyme caused bacterial resistance to the penicillins, cephalosporins 
 
including the extended spectrum and aztreonam (but not to cephamycins or 
 
carbapenems). However they were inhibited by beta-lactamase inhibitors such as 
 
clavulanic acid, sulbactam and tazobactam (Bush, 2011). The most common ESBLs 
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 are SHV- and TEM- with the CTX-M were increasingly detected worldwide (Paterson 
 
, 2005). TEM-1, TEM-2, and SHV-1 were conferring resistance to ampicillin, 
amoxicillin, and other penicillins, as well as to early but still sensitive to 3
rd 
generation 
cephalosporin. However, some of Enterobacteriaceae members especially those 
commonly causing hospital acquired infection like Klebsiella pneumoniae began to 
produce mutated versions of these beta-lactamases that made them resistant to third-
generation cephalosporins and to the monobactam aztreonam. According to 
the National Nosocomial Infections Surveillance (NNIS) System report, in 2003, 
about 20.6% of K.pneumoniae, 31.1% of Enterobacter spp and 5.8% of E.coli 
isolated from patients in ICU were nonsusceptible to third generation cephalosporin 
(CDC, 2004). In a study of patients with ESBL-producing K.pneumoniae bacteremia, 
54% of patients receiving treatment with a susceptible cephalosporinas determined by 
in vitro methods, experienced clinical failure (Paterson, 2001). Subgroup analysis from 
a randomized, evaluator-blind trial comparing cefepime with imipenem in patients 
with nosocomial pneumonia showed that 100% of patients receiving imipenem for 
pneumonia caused by an ESBL producer experienced a positive clinical response 
compared with only 69% of patients treated with cefepime (Zanetti, 2003). A 
prospective, observational study of patients with K.pneumoniae bacteremia reported 
an all cause14-day mortality rate of 3.7% with carbapenem alone, compared with 
rates of 36.3% and 44.4% with quinolone and noncarbapenem beta-lactam 
monotherapy, respectively (Paterson, 2004). Thus, carbapenems currently considered to 
be the most preferred agents for treatment of serious infections caused by Enterobacter 
spp and ESBL-producing Enterobacteriaceae. These drugs were highly stable to beta-
lactamase hydrolysis, and porin penetration is facilitated by their general size and 
structure. 
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 1.2 Carbapenem Resistant Enterobacteriaceae (CRE) 
 
 
 
1.2.1 Definition 
 
 
 
The previous Centers for Disease Control and Prevention (CDC) CRE definition 
based on 2012 CRE toolkit is an Enterobacteriaceae that nonsusceptible to imipenem, 
meropenem, or doripenem and also resistant to all third generation cephalosporins. 
However, in the development of molecular method, it was found that this definition 
might miss some carbapenamase producing CRE (CP-CRE). CDC began to identify 
CRE that were positive for the KPC gene and were resistant to ertapenem that not 
included in previous definition but still susceptible to the other carbapenems (Arnold et 
al., 2011). Other than that, CRE producing OXA-48-type carbapenemases might not 
exhibit resistance to third-generation cephalosporins which might be missed by the 
previous definition (Singh-Moodley and Perovic, 2016). The pre-2015 CDC CRE 
surveillance definition was found misclassified nearly 13% of carbapenem-
nonsusceptible Klebsiella spp. isolates and 21% of KPC-producing Klebsiella 
spp. isolates as non–carbapenemase producing (Nora et al., 2015). 
 
The ability to detect CP-CRE is an important component of outbreak investigations as 
 
it‟s possess a more stable and transferable form of resistance and this resistance can 
 
spread through either clonal expansion or transfer of carbapenemase genes to naive 
 
bacteria (Nordmann P, 2011). In an attempt to further increase the ability to 
identify CRE that produce carbapenemases, CDC in January 2015 has modified 
the CRE definition to Enterobacteriaceae which was resistant to imipenem, 
meropenem, doripenem, or ertapenem or documentation of carbapenemase 
production from the isolates. Ertapenem which included in the new definition is the  
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 most sensitive indicator in detecting KPC-producing strain which has moderately high 
positive predictive value (79%) with a very high specificity (99.2%) (McGettigan 
et al., 2009). In some Enterobacteriaceae which intrinsically elevated minimum 
inhibitory concentration (MICs) to imipenem including Proteus spp., 
Morganella spp. and Providencia Spp (CLSI and Wayne, 2012) the imipenem 
resistance alone does not consider as CRE. The other carbapenems which are 
meropenem, doripenem, and ertapenem should be used for these organisms to 
determine if these organisms meet the CRE definition. 
 
There were several methods available for detecting carbapenamases with the acceptable 
 
methods by CDC including polymerase chain reaction (PCR), Carba-NP test and 
 
mettalo-β-lactamase testing such as Modified Hodge Test (MHT). The MHT was 
widely used in clinical laboratories as it was simple and inexpensive with 
documented good sensitivity between 93% to 98% for many carbapenemases, including 
VIM, IMP, and OXA-48-like enzymes except NDM (Vasoo and Lolans, 2013). A 
new CDC 2015 CRE definition which included a MHT was able to reduce the false 
positive result from 55% to 12% especially involving the less likely organism to 
produce carbapenamases such as Enterobacter spp (Nora et al., 2015) 
 
As the above phenotypic definition lacks specificity for CP-CRE, the CDC had 
 
encouraged clinical and public health laboratories which have the capacity to perform 
 
molecular method to test carbapenem resistance mechanism in order to detect the 
 
presence of carbapenemases especially KPC, NDM and OXA-48-type carbapenemases 
 
enzyme. 
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 1.2.2 Epidemiology 
 
 
 
CRE especially CP-CRE has emerged as a global threat with the carbapenemases in 
 
Enterobacteriaceae have been reported increasingly in the past 10 years (Thaden et 
al., 2014, Nordmann, 2011). The spread was quite worrisome as it not constrained to 
a particular geographical location anymore with the current ease of travel and 
global migration. Klebsiella pneumoniae carbapenemases (KPC) have been reported 
in the United States and then worldwide, with a marked endemicity at least 
in the United States (Cerqueira et al., 2017). Metalloenzymes (Verona integron-
encoded metallo-β-lactamase, IMP) also have been reported worldwide, with a 
higher prevalence in Mediterranean countries. Carbapenemases of the 
oxacillinase-48 (OXA) type have been identified mostly in North Africa and West 
Europe (Nordmann et al., 2011a). Recently, a New Delhi metallo-beta-lactamase 
(NDM) carbapenemases which originally identified in Sweden in 2008 have been 
spread worldwide rapidly (Dortet et al., 2014). 
 
In Asia, the prevalence rate of CRE was still low with the rates of resistance to 
 
impenem and meropenem in Enterobacteriaceae are 0.8% and 1.0% respectively in a 
 
study period of 2001 to 2012 but it shows increasing in trend (Xu et al., 2015). 
 
However, this data only was provided by 19 countries out of 49 Asia countries with the 
 
Malaysia CRE prevalence rate was reported about 1% to 5%. The most common CRE 
 
isolated in Asia was Klebsiella spp. (39.26%) followed by E.coli (21.97%), Serratia 
 
spp. (19.80%), Enterobacter spp. (12.97%), Proteus spp. (3.95%) and Citrobacter spp. 
 
(2.0%). K. pneumoniae was the most prevalent species in various conducted study in 
 
many regions including in US (Guh et al., 2015, Thaden et al., 2014), Asia pacific 
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 region; Taiwan (Tang et al., 2016) and Singapore (Ling et al., 2015). However, 
the bacterial distribution of CRE isolates may vary every region thus 
surveillance investigation should be perform to establish its own epidemiological 
characteristics. 
 
Based on unpublished data from National Alert Organism Surveillance 2016, overall the 
 
incidence rate of CRE in Malaysia was increased in trend from year 2013 to 2015. 
 
However, the rate was static from year 2015 to 2016 with the incidence rate of 0.05 of 
 
total isolates per 100 admissions even though the frequency of CRE cases have been 
 
reported in 2016 increasing in trend (unpublished data 2016, MOH). Most of CRE 
was recovered from blood sample (26.4%) followed by urine (21.2%), rectal swab 
(20.1%) and tracheal aspirate (8.4%) with the third most common CRE isolated were 
K. pneumoniae (76.4%), E. coli (10.4%) and Enterobacter spp. (5.6%). About 
46.3% of isolates were related to true infection which was quite close with others 
study (Thaden et al., 2014) with the 59.9% causing blood stream infection, 
13.5% UTI, 7.7% pneumonia, 4.8% SSI and others. Carbapenamases gene detection 
of the total isolates revealed that the NDM-1 was the most common responsible gene 
which was about 78% followed by OXA-48 (6.14%), OXA-181 (3.46%) and the 
others rare genes that were detected including KPC, IMP and VIM. It was found that 
about 4% of the total isolates in 2016 were resistant to polymixin. In the study area 
within 2013 to 2015 period, it was found that Klebsiella pneumoniae was the 
predominant species (95%) with the genotype determination shows about 82.4% were 
positive for New Delhi metallo-β-lactamase 1 (NDM-1) gene (blaNDM1) (Zaidah et al., 
2017). 
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 Most of the CRE infections are related to healthcare setting which was about 70 to 90% 
 
of the cases (Thaden et al., 2014, Tang et al., 2016). Those patients were acquired 
 
infection after 48 hour of hospital admission or with the presence of previous 
 
hospitalization, surgery, dialysis, or residence in a long-term care facility in the 12 
 
months preceding identification or with the presence of an invasive device. There were 
 
several risk factors have been identified associated with acquisition of CRE infections 
 
in various study, including exposure to antibiotics, healthcare exposure, presence of 
 
indwelling devices, use of mechanical ventilator, and with the presence of co 
 
morbidities especially diabetes mellitus, chronic renal failure and immunodeficiency 
 
patients (Ling et al., 2015, Wang et al., 2016). However, it has been reported about 30% 
 
of CRE infections were acquired from community settings in Taiwan (Tang et al., 2016) 
 
and 6% in the south eastern United States (Thaden et al., 2014). The most common 
 
community acquired infection related to CRE was urinary tract infection followed by 
 
pneumonia which mostly occurred in elderly (Tang et al., 2016). 
 
 
 
1.2.3 Mechanisms of resistance. 
 
 
There were two main mechanisms of carbapenems resistant in CRE which by the 
 
production of 𝛽-lactamases (cephalosporinase ; AMP-C β-lactamase and ESBL) in 
 
combination with decreased permeability due to porin loss or by the production of a 
 
carbapenem-hydrolyzing 𝛽-lactamase (carbapenamase) that able to hydrolyze the 
 
carbapenems itself (Nordmann et al., 2011a). Porins were hydrophilic protein channels 
 
that located at the outer membranes of Enterobacteriaceae which allow essential 
 
nutrients uptakes for bacterial survival. The presence of these porins also allows the 
 
transport of antibiotics across the outer membrane of these bacteria into the periplasmic 
 
space. In K.pneumoniae, there were two major porins involved with this function which 
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 OmpK35 and OmpK36 that homologous to OmpF and OmpC in E.coli (Tsai et al., 
 
2011). The absence or modification of these porins will lead to decrease the 
 
permeability of these bacteria to the antibiotics. The combination of AMP-C β- 
 
lactamases or ESBL with the porin loss usually associated with low level of resistant of 
 
carbapenems and commonly affected ertapenem more than meropenem or 
 
imipenem (Domenech-Sanchez et al., 2003) . 
 
 
The most concern mechanism of resistant in CRE was a consequence of acquisition of 
 
carbapenemase genes as it usually associated with high level of resistant to 
 
carbapenems and has been spread worldwide (Queenan and Bush, 2007). These 
 
carbapenamases resistant genes resides in the mobile genetic elements including 
 
transposons, integrons or plasmid causing potential spread even to the naive bacteria. 
 
There were large variety of carbapenemases have been identified in Enterobactericeae 
 
that were classified in 3 classes of Ambler molecular classification based on amino acid 
 
homology which Ambler class A, B and D β-lactamases. They were different in terms 
 
of active site of hydrolysing beta lactams whereby class A and D required a serine 
 
residue at their active site, whereas class B need zinc for their activities. Details on each 
 
class were discussed below. 
 
 
1.2.3.1 Class A Carbapennemases 
 
 
There were three major families of class A serine carbapenemases include the NMC 
 
(not metalloenzyme carbapenemase)/IMI (imipenem-hydrolyzing β-lactamase), SME 
 
(Serratia marcescens enzyme ), and KPC enzymes. The other rare carbapenamase that 
 
previously regard as ESBL is GES (Guiana extended spectrum). These carbapenamases 
 
can be chromosome encoded including NmcA, Sme and IMI-1or plasmid encoded 
 
including KPC, IMI-2 and GES. All have the ability to hydrolyze a broad variety of β- 
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 lactams including carbapenems, cephalosporins, penicillins, and aztreonam but they 
 
were inhibited by clavulanate and tazobactam. KPCs were the most common class A 
carbapenamase that was first identified in 1996 in the United States (Yigit et al., 2001) 
then was spread globally in a few years. Although the KPC β-lactamases are 
predominantly found in K.pneumoniae, there have been reports of these enzymes in 
other species including Enterobacter spp. and in Salmonella spp. (Bratu, 2005, 
Miriagou and Whichard., 2003). KPC carbapenemases hydrolyzed all classes of β-
lactams especially penicillins and early cephalosporin but 10-fold-less efficiently to 
hydrolize cefotaxime and aztreonam (Queenan and Bush, 2007). The level of resistance 
to carbapenems of KPC producers may vary markedly with the ertapenem was the 
lowest activity (Nordmann et al., 2011a). The important of KPC family was it has the 
greatest potential for spread due to its location on plasmids, especially since it was 
most frequently found in K.pneumoniae, an organism notorious for its ability to 
accumulate and transfer resistance determinants. 
 
1.2.3.2 Class B Metallo-B- Lactamases 
 
 
 
The most common class B enzymes involved in CPE including Verona integron- 
 
encoded metallo-beta-lactamase (VIM), imipinemase metallo-beta-lactamase (IMP) and 
 
New Delhi metallo-beta-lactamase (NDM). The first acquired MBL, IMP-1, was 
 
reported in Serratia marcescens in Japan 1994 (Osano et al., 1994). These enzymes 
 
hydrolyze all β-lactams except aztreonam and their activity was inhibited by ethylene 
 
diamine tetra acetic acid (EDTA) but not by clavulinic acid. Resistance levels to 
carbapenems in MBL producers may vary. Recently, the NDM-1 β-lactamase enzymes 
give a major concern as it has been reported to occur in various bacterial species all 
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 over the world since it was first reported in 2009 (Yong et al., 2009). Although most 
of the NDM-producing strains identified were Enterobacteriaceae, this carbapenemase 
has also been reported from Acinetobacter spp. and more rarely from P. Aeruginosa 
(Dortet et al., 2014). The widespread dissemination of blaNDM-1 was mainly 
due to promiscuous plasmids and clonal outbreaks. Compared with other 
carbapenamases, NDM-1 has deeply disconcerting for public health worldwide as it 
was not only easily to spread but may cause pan drug resistance as plasmids carrying 
the blaNDM-1 gene can harbor a high number of resistance genes associated with 
other carbapenemase genes (OXA-48 types, VIM types), plasmid-mediated 
cephalosporinase genes, ESBL genes, aminoglycoside resistance genes (16S RNA 
methylases), macrolide resistance genes (esterase), rifampin (rifampin modifying 
enzymes) and sulfamethoxazole resistance genes (Kumarasamy et al., 2010, 
Nordmann et al., 2011b). 
 
 
1.2.3.3 Class D Enzymes of the OXA Type 
 
 
Class D β-lactamases, also known as OXA-type enzymes or oxacillinases, were 
 
represented by more than 350 genetically diverse enzymes that widely disseminated in 
 
Gram-negative bacteria. They were not inhibited by clavulanic acid, tazobactam, and 
 
sulbactam but inhibited in vitro by sodium chloride (NaCl). They were broadly 
 
classified into narrow- and extended-spectrum enzymes based upon the conferred 
 
resistance profile against β-lactam antibiotics. Class D carbapenemases, also known as 
 
carbapenem-hydrolyzing class D β-lactamases (CHDLs) (Poirel et al., 2010), represent 
a further expansion of the substrate profile of class D enzymes to include 
carbapenem antibiotics. CHDLs have been subdivided into several subgroups based on 
their amino acid sequence identity and those enzymes belonging to the OXA-23, 
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 OXA-24/40, OXA-48, OXA-51, OXA-58, and OXA-143 subgroups of a major 
clinical importance due to their wide dissemination in bacterial pathogens. The 
majority of these carbapenemases, have been identified in various Acinetobacter 
isolates, predominantly in Acinetobacter baumannii except for OXA-48 (Evans et 
al., 2013). OXA-48 first identified from carbapenem-resistant K. pneumoniae isolates 
in Turkey, 2001 (Poirel et al., 2004) and this enzyme has spread among other 
members of the Enterobacteriaceae family including E.coli and Enterobacter spp. 
(Poirel et al., 2012b). This enzyme hydrolyses penicillins at a high level and 
carbapenems at a low level, sparing broad- spectrum cephalosporins especially 
ceftazidime and cefepime but was not susceptible to β-lactamase inhibitors. When 
combining permeability defects or with the presence of ESBL, OXA-48-like 
producers may exhibit a high level of resistance to carbapenems(Poirel et 
al., 2004). The OXA-48 enzyme was a plasmid encoded (blaOXA-48 gene) and it 
was not associated with an integron, in contrast to most of the oxacillinase genes. 
Molecular investigations showed that plasmid pOXA-48a was identified in all 
OXA-48-producing isolates recovered from many countries (Poirel et al.,2012a). 
 
1.2.4 Laboratory diagnosis 
 
 
The detection of CRE especially CP-CRE is very important for infection control 
measure along with patient‟s management itself. The confirmation of 
Enterobactericeae family should be done first by morphological characteristic of 
colonies, gram stain and biochemical testing. In difficult identification of the species 
an automated system may be required such as VITEK 2 System, Microscan and 
others. Then, those isolates that were suspected of CRE based on antibiotic 
susceptibility testing (disc diffusion method) towards carbapenems will proceed to 
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 confirmatory test. Confirmation of CRE based on CDC definition has been discussed 
before either by knowing the MICs level of all carbapenems, phenotypic tests to 
demonstrate the presence of carbapenamases enzymes or by molecular method. 
 
1.2.4.1 Culture method 
 
 
 
Enterobacteriaceae can be grown on various basic and selective media such as nutrient 
 
agar, MacConkey agar and blood agar. The isolates should be incubated in an incubator 
 
at 35˚C for 20 to 24 hours. Their colonies can be differentiate on MacConkey agar 
 
based on their lactose fermenter properties. Certain Enterobactericeae family can 
 
produce a special colonies pigment which can help in identification of this organism 
 
such as Serratia marcescens that produced red pigment. 
 
 
 
1.2.4.2 Biochemical Tests 
 
 
 
The basic biochemical test including triple sugar iron reaction, motility, indole, citrate, 
 
urease, methyl red and voges-prosakaur allows the differentiation of the various 
 
members of Enterobacteriacea. In difficult identification, an extended biochemical 
 
testing may be required either by using manual identification products such as API 20E 
 
or automated systems such as Vitek2 System (GN card). 
 
 
 
1.2.4.3 Antibiotic Susceptibility Testing (AST) 
 
 
 
The detection of CRE in clinical laboratory was based on susceptibility testing results 
 
obtained either via automated systems, liquid media, e test and disk diffusion 
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 tests (Nordmann et al., 2012a). AST is in vitro testing of bacterial cultures 
with antibiotics which were used to determine susceptibility of bacteria to a 
specific antibiotic therapy. Generally, the AST can be done by dilution, diffusion or 
combination method which known as antimicrobial gradient method or Epsilometer test 
(E test). 
 
The optimal interpretation of susceptibility test requires knowledge of the 
 
pharmacokinetics of the drugs in humans and the ability of particular drug in eradicating 
 
bacteria at various body sites. It should be referred to an expert source such as the CLSI. 
 
The CLSI zone size and MIC interpretive criteria are established by analysis of 3 kinds 
 
of data : (1) microbiologic data, including a comparison of MICs and zone sizes on a 
 
large number of bacterial strains, including those with known mechanisms of resistance 
 
that have been defined either phenotypically or genotypically; (2) pharmacokinetic and 
 
pharmacodynamic data; and (3) clinical studies results (including comparisons of MIC 
 
and zone diameter with microbiological eradication and clinical efficacy) obtained 
 
during studies prior to FDA approval and marketing of an antibiotic (Wayne, 2008). 
It provide break points for both MIC values and disk diffusion zone diameters for 
all relevant antibiotics most of the bacterial genera which give the clinical 
interpretation of susceptibility to susceptible, intermediate or resistant. A “susceptible” 
result indicates that the organism should respond to therapy with that antibiotic using 
the dosage recommended normally for that type of infection and species. 
Conversely, an organism with a MIC or zone size interpreted as “resistant” should 
not be inhibited by the concentrations of the antibiotic achieved with the dosages 
normally used with that drug. An “intermediate” result indicates that a microorganism 
falls into a range of susceptibility in which the MIC approaches or exceeds the level of  
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 antibiotic that can ordinarily be achieved and for which clinical response is likely to be 
less than with a susceptible strain. Most of the clinical laboratory used CDC definition 
for the diagnosis of CRE by using the break point of carbapenems from CLSI 
guideline. The revised interpretative criteria for carbapenems were published by 
Clinical and Laboratory Standards Institute in CLSI M-100-S20-U, June 2010 
lowered the carbapenems breakpoint significantly with addition of doripenem 
breakpoint to permit better detection of carbapenem-resistant isolates. Details of the 
carbapenems break point were presented in the Table 1. 
 
 
Table 1 Carbapenems breakpoints according to CLSI 2012 (M100-S26). 
 
 
 
Carbapenems S I R 
 
Doripenem 
 
<1 
 
2 
 
 
>4 
Ertapenem <0.5 1 >2 
Imipenem <1 2 >4 
Meropenem <1 2 >4 
 
 
 
 
1.2.4.3.1 Dilution method 
 
 
Dilution susceptibility testing methods were used to determine the minimal 
concentration of antimicrobial to inhibit growth of the microorganism or also known 
as minimal inhibitory concentration (MIC). This can be achieved by dilution   
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 of antimicrobial in either agar or broth media. Antimicrobials were tested in log2 
serial dilutions (two fold). The macrobroth or tube-dilution method was one of the 
earliest AST methods (Ericsson and Sherris, 1971). This procedure involved preparing 
two-fold dilutions of antibiotics in a liquid growth medium dispensed in test tubes 
with the antibiotic containing tubes were inoculated with a standardized bacterial 
suspension. The tubes were examined for visible bacterial growth as evidenced by 
turbidity after overnight incubation at 35˚C. The MIC expressed as the lowest dilution, 
which inhibited growth judged by lack of turbidity in the tube. 
 
 
The main advantage of the „broth dilution‟ method for the MIC determination lies in 
 
the fact that it can readily be converted to determine the minimum bactericidal 
 
concentration (MBC) as well. This method has been simplified by the used of small, 
 
disposable and plastic “microdilution” trays thus, it was namely as microbroth dilution 
 
method. The agar dilution technique has advantage in terms of the ability to test several 
 
organisms on each plate. The presence of bacterial colonies on the plates after 
 
incubation indicates growth (Wiegand et al., 2008). The MIC in this technique was the 
 
antibiotic concentration of the first plate showing  99% inhibition. The major 
 
disadvantages of this method were due to labour intensive, time consuming and have a 
 
higher cost. 
 
 
1.2.4.3.2 Diffusion method 
 
 
Diffusion tests or also known as disc diffusion method was widely used to determine 
 
the susceptibility of organisms isolated from clinical specimens as it was simple, 
 
practical and has been well standardized. There were two method of disc diffusion test 
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 which the Kirby-Bauer and Stokes' methods with the Kirby-Bauer method being 
 
recommended by the Clinical Laboratory Standards Institute (CLSI). The test was 
performed by inoculated a standardized bacterial inoculum to the Mueller-Hinton agar 
plate followed by placement of antimicrobial disks. The disks used for a disk 
diffusion assay contain a standardized known amount of an antimicrobial agent, 
which diffuse into agar when in contact with the agar surface. The zones of growth 
inhibition around each of the antibiotic disks are measured to the nearest millimetre 
after incubated under standardized conditions. The diameter of the zone is related to the 
susceptibility of the isolate and to the diffusion rate of the drug through the agar 
medium. The zone diameters of each drug are interpreted using the criteria published by 
the CLSI which provide a “qualitative” rather than MIC that categorized as susceptible, 
intermediate, or resistant. Many variables can influence the zone sizes such as depth of 
agar, inoculums density and the size or molecular weight of tested antibiotics that can 
affected the diffusion process which can lead to unreliable results. In view of those 
limitations; when equivocal results are obtained or in prolonged serious infection e.g. 
bacterial endocarditis, the quantitation of antibiotic action vis-a-vis the pathogen needs 
to be more precise by doing the test that able to determine the MIC of the antibiotic to 
the organisms concerned. 
 
The disk diffusion breakpoints identified a much higher proportion of the 
 
carbapenemase producers than the MIC breakpoints thus, it was a useful tool in 
 
screening for CP-CRE especially for KPC-producing and VIM-producing K. 
 
pneumoniae (Vading et al., 2011). 
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 1.2.4.3.3 Epsilometer test (E test) 
 
 
E test also known as the epsilometer test was an antimicrobial gradient diffusion method 
 
uses the principle of establishment of an antimicrobial concentration gradient in an agar 
 
medium as a means of determining susceptibility. The E test was a quantitative method 
 
for antimicrobial susceptibility testing applies both the dilution of antibiotic and 
 
diffusion of antibiotic into the medium. A predefined stable antimicrobial gradient was 
 
present on a thin inert carrier strip and once this E test strip applied onto an inoculated 
 
agar plate, there was an immediate release of the drug. Following incubation, a 
 
symmetrical inhibition ellipse will be produced. The intersection of the inhibitory zone 
 
edge and the calibrated carrier strip indicates the MIC value over a wide concentration 
 
range (>10 dilutions) with inherent precision and accuracy. Generally, E test results 
 
have correlated well with MICs generated by broth or agar dilution methods (Rennie et 
 
al., 2012, Baker et al., 1991). 
 
 
 
1.2.4.4 Automated systems 
 
 
 
There are 4 automated instruments presently cleared by the FDA for use in the United 
 
States with three of these can generate rapid (3.5 to16 hours) susceptibility test results 
 
including MicroScan WalkAway, BD Phoenix Automated Microbiology System and 
 
Vitek 2 System while the fourth is an overnight system which was Sensititre ARIS 2X 
 
(Trek Diagnostic Systems). This instrumentation can provide a standardize reading of 
 
end points and often produce susceptibility test results in a shorter period than manual 
 
readings as it has a sensitive optical detection systems that allow detection of subtle 
 
changes in bacterial growth. It have been shown that providing rapid susceptibility test 
 
results can lead to more timely changes to appropriate antimicrobial therapy, substantial 
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